Antiplatelet Secondary Prevention International Randomised Trial After INtracerebral HaemorrhaGe (ASPIRING)-Pilot Phase

PHASE3CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

September 3, 2021

Primary Completion Date

October 13, 2023

Study Completion Date

October 13, 2023

Conditions
Intracerebral Hemorrhage
Interventions
DRUG

Start antiplatelet monotherapy

Start one antiplatelet drug, be available in local standard clinical practice, chosen by patient's physician pre-randomisation

Trial Locations (2)

100088

The George Institute for Global Health, Beijing

200000

Huashan Hospital, Fudan University, Shanghai

All Listed Sponsors
collaborator

University of Edinburgh

OTHER

collaborator

Huashan Hospital

OTHER

collaborator

The University of Western Australia

OTHER

lead

The George Institute for Global Health, China

OTHER

NCT04522102 - Antiplatelet Secondary Prevention International Randomised Trial After INtracerebral HaemorrhaGe (ASPIRING)-Pilot Phase | Biotech Hunter | Biotech Hunter